Medical Researcher: We recently concluded a six-month clinical trial of Cardioxil, a new medication for elevated blood pressure. Over the course of the trial, 75 percent of the participants experienced a significant decrease in their blood pressure. Furthermore, among the participants who experienced this decrease, the only reported side effect was occasional mild dizziness. Therefore, Cardioxil is highly effective at lowering blood pressure and presents no serious health risks to those who use it.
Which of the following, if true, most seriously weakens the medical researcher's argument?
- AIn a separate control group that received a placebo instead of Cardioxil, the rate of occasional mild dizziness was identical to that of the experimental group.
- BSeveral other blood pressure medications currently on the market are equally effective as Cardioxil but do not cause occasional mild dizziness.
- Participants in the trial who did not experience a decrease in blood pressure suffered severe, life-threatening organ damage caused by Cardioxil.Cevap
- DSubsequent clinical trials have demonstrated that Cardioxil does not actually produce a significant decrease in blood pressure for the vast majority of patients.
- EElevated blood pressure is typically caused by lifestyle factors, such as diet and lack of exercise, which Cardioxil is not designed to address.
Cevap
The option stating that participants who did not experience a decrease in blood pressure suffered severe, life-threatening organ damage.
The argument concludes that Cardioxil presents no serious health risks based solely on the side effects reported by the 75% of participants who experienced a decrease in blood pressure. This creates a critical logical gap by completely ignoring the side effects experienced by the remaining 25% of participants. The correct answer exploits this scope limitation by introducing new evidence that this omitted group suffered catastrophic, life-threatening organ damage. This directly targets the reasoning gap and demolishes the conclusion that the medication presents no serious health risks to its users.
Adım Adım Çözüm
Anahtar Kavram
Scope Shifts and Selection Bias in Evidence